Treatment of cancers with acquired resistance to kit inhibitors
OwnerScott Wilhelm, Gedrich Richardinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.
Claims29
A method of treating a cancer in a subject in need thereof, wherein said cancer was initially sensitive to KIT tyrosine kinase inhibitor and acquired resistance to said KIT tyrosine kinase inhibitor, said method comprising:
- administering to said subject, an effective amount of the tosylate salt of the compound N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea of the formula I below including all polymorphs, hydrates, solvates or combinations thereof.
A method of treating a cancer in a subject in need thereof said cancer having a primary and/or secondary KIT gene mutation in the primary tumor, said method comprising:
- administering to said subject, an effective amount of the tosylate salt of the compound N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea of the formula I below including all polymorphs, hydrates, solvates or combinations thereof.
A method of treating a cancer in a subject in need thereof said cancer having a primary and/or secondary KIT gene mutation associated with resistance or acquired resistance to imatinib mesylate, derivatives of imatinib mesylate or salts of imatinib mesylate, said method comprising:
- administering to said subject, an effective amount of the tosylate salt of the compound N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea of the formula I below including all polymorphs, hydrates, solvates or combinations thereof.
A method for treating cancer in a human subject with imatinib mesylate, derivatives of imatinib mesylate, or salts of imatinib mesylate, which additionally comprises:
- administering to said human subject, an effective amount of the tosylate salt of the compound N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea of the formula I below including all polymorphs, hydrates, solvates or combinations thereof.
A method of treating a cancer in a subject who has acquired resistance to imatinib, comprising:
- administering an effective amount of sorafenib to said subject.
Dependencies are inferred from the claim text.